BR112014012277A2 - composição farmacêutica para tratamento de reações alérgicas - Google Patents

composição farmacêutica para tratamento de reações alérgicas

Info

Publication number
BR112014012277A2
BR112014012277A2 BR112014012277A BR112014012277A BR112014012277A2 BR 112014012277 A2 BR112014012277 A2 BR 112014012277A2 BR 112014012277 A BR112014012277 A BR 112014012277A BR 112014012277 A BR112014012277 A BR 112014012277A BR 112014012277 A2 BR112014012277 A2 BR 112014012277A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
allergic reactions
inhibitor
treatment
matrix
Prior art date
Application number
BR112014012277A
Other languages
English (en)
Inventor
B Schmidt-Weber Carsten
Grunwald Thomas
Original Assignee
Helmholtz Zentrum München Forschungszentrum Für Gesundheit Und Umwelt Gmbh
Pls Design Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum München Forschungszentrum Für Gesundheit Und Umwelt Gmbh, Pls Design Gmbh filed Critical Helmholtz Zentrum München Forschungszentrum Für Gesundheit Und Umwelt Gmbh
Publication of BR112014012277A2 publication Critical patent/BR112014012277A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "composição farmacêutica para tratamento de reações alérgicas". a presente invenção refere-se a uma composição farmacêutica feita de uma ou mais preparações e compreendendo uma dose fisiologicamente eficaz de pelo menos um inibidor de il-4 e/ou il-13 e pelo menos um alérgeno, e uma matriz, em que pelo menos o inibidor é solvido ou incorporado, ou sobre o qual pelo menos o inibidor é revestido ou adsorvido, em que a matriz é selecionada de modo a permitir liberação prolongada do inibidor. 21336005v1 1/1 21336005v1
BR112014012277A 2011-11-23 2012-11-23 composição farmacêutica para tratamento de reações alérgicas BR112014012277A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11075261.5A EP2596802A1 (en) 2011-11-23 2011-11-23 Pharmaceutical composition for treatment of allergic reactions
PCT/EP2012/004884 WO2013075846A1 (en) 2011-11-23 2012-11-23 Pharmaceutical composition for treatment of allergic reactions

Publications (1)

Publication Number Publication Date
BR112014012277A2 true BR112014012277A2 (pt) 2019-09-24

Family

ID=47358079

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014012277A BR112014012277A2 (pt) 2011-11-23 2012-11-23 composição farmacêutica para tratamento de reações alérgicas

Country Status (6)

Country Link
US (2) US20140335162A1 (pt)
EP (1) EP2596802A1 (pt)
CN (1) CN104039349A (pt)
BR (1) BR112014012277A2 (pt)
IN (1) IN2014DN03429A (pt)
WO (1) WO2013075846A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2813242A1 (en) * 2013-06-13 2014-12-17 PLS-Design GmbH Low molecular weight immune-modulators as adjuvants for specific immunotherapy
EP2918262B1 (en) * 2014-03-10 2023-08-09 PLS-Design GmbH Induction of antigen-specific tolerance by peripheral phagocytosis
EP3237003B1 (en) * 2014-12-24 2021-08-11 NexImmune, Inc Nanoparticle compositions and methods for immunotherapy
CN105727371B (zh) * 2016-01-25 2019-04-09 北京天助畅运医疗技术股份有限公司 腹壁疝修补材料
CN107669638B (zh) * 2017-10-23 2020-05-22 华南理工大学 一种peg-pcl-peg三嵌段共聚物修饰的羟基积雪草苷脂质体及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
DE4137333A1 (de) 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
TR199802591T2 (xx) 1996-06-14 1999-04-21 Bayer Corporation T-H�cresi se�ici interl�kin-4 agonistleri
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
KR100633939B1 (ko) 1997-10-03 2006-10-16 마크로메드 인코퍼레이티드 가역적 열 겔화 성질을 갖는 생분해성 저분자량 트리블럭폴리(락티드-코-글리콜리드) 폴리에틸렌 글리콜 공중합체
CA2322435A1 (en) * 1998-03-02 1999-09-10 Applied Vaccine Technologies Corp. Methods and devices for modulating the immune response
CN1299272A (zh) * 1998-03-02 2001-06-13 应用疫苗技术公司 调节免疫应答的方法及装置
US6841617B2 (en) * 2000-09-28 2005-01-11 Battelle Memorial Institute Thermogelling biodegradable aqueous polymer solution
WO2001039800A2 (en) * 1999-12-06 2001-06-07 The Board Of Trustees Of The University Of Arkansas Controlled delivery of antigens
DE16192152T1 (de) 2000-05-26 2020-08-06 Immunex Corporation Verwendung von interleukin-4 rezeptor (il-4r) antikörpern und zusammensetzungen davon
WO2002004009A2 (en) 2000-07-12 2002-01-17 Immunex Corporation Method for treating cancer using an interleukin- 4 antagonist
US20030003074A1 (en) 2001-06-14 2003-01-02 Macromed, Inc. Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
ATE378427T1 (de) 2005-10-17 2007-11-15 Rina Netzwerk Rna Technologien Verfahren zur bestimmung einer unbekannten pns seqenz und seine verwendungen
EP1984015A4 (en) * 2006-01-11 2011-11-30 Aerovance Inc METHOD AND COMPOSITIONS FOR TREATING ASTHMA IN HUMANS AND OTHER PRIMATES
US10736848B2 (en) * 2007-10-12 2020-08-11 Massachusetts Institute Of Technology Vaccine nanotechnology
CA2708871C (en) 2007-12-21 2017-11-21 Medimmune Limited Binding members for interleukin-4 receptor alpha (il-4r.alpha.) - 173
ES2525648T3 (es) * 2009-01-28 2014-12-26 Novartis Ag Formulaciones galénicas que comprenden Aliskiren
JP5656370B2 (ja) 2009-07-01 2015-01-21 キヤノン株式会社 画像処理装置、画像処理システム、画像処理方法、およびプログラム

Also Published As

Publication number Publication date
US20180117143A1 (en) 2018-05-03
US20140335162A1 (en) 2014-11-13
WO2013075846A1 (en) 2013-05-30
EP2596802A1 (en) 2013-05-29
IN2014DN03429A (pt) 2015-06-05
CN104039349A (zh) 2014-09-10

Similar Documents

Publication Publication Date Title
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112012021364A2 (pt) "compostos cicloalquila contendo tienopirimidinas e composições farmacêuticas".
BR112014008731A2 (pt) tratamento de esclerose múltipla com combinação de laquinimode e fingolimode
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
CR20120638A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
BR112013022789A2 (pt) composições farmacêuticas que compreendem metformina e um inibidor dpp-4 ou um inibidor sglt-2
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BR112014015955A2 (pt) uso terapêutico subcutâneo de inibidor de dpp-4
BR112015022417A2 (pt) métodos e composições para inibição de proteínas contendo bromodomínio
BR112012009376A2 (pt) composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso
BR112015006623A2 (pt) laquinimod e pridopidina para o tratamento de doenças neurodegenerativas
BR112014010291A2 (pt) composições de lipossoma combinacionais para terapia de câncer
BR112013008601A8 (pt) Formulações de emulsão de clevidipina contendo agentes antimicrobianos
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BR112014012277A2 (pt) composição farmacêutica para tratamento de reações alérgicas
BR112012022552A8 (pt) uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos
BR112012005044B8 (pt) composição farmacêutica que compreende uma combinação de (rac)-tramadol·hcl e celecoxib
BR112015022650A8 (pt) inibidores de quinase induzível por sal macrocíclico.
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
BR112015011430A2 (pt) composição para liberação imediata e prolongada
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
BR112013027486A2 (pt) combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.